Innovent Biologics, Inc.

As of June 30, 2026, Innovent Biologics Inc. carries a market capitalization of 17.45B, placing it among publicly traded companies globally. Its enterprise value stands at 14.85B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Innovent Biologics Inc.'s next confirmed earnings release is scheduled for March 31, 2027.

As of June 30, 2026, Innovent Biologics Inc. has 434.71M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Innovent Biologics Inc. maintains a current ratio of 2.68, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Innovent Biologics Inc.'s stock has declined approximately 9.86% over the past 52 weeks.

As of June 30, 2026, Innovent Biologics Inc. holds 2.95B in cash and equivalents against 342.42M in total debt, resulting in a net debt position of -2.22B. Total book value stands at 3.06B, with working capital of 2.31B providing operational flexibility.